Cwm LLC Buys 8,772 Shares of Edwards Lifesciences Corporation (NYSE:EW)

CWM LLC boosted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 36.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,916 shares of the medical research company's stock after buying an additional 8,772 shares during the quarter. CWM LLC's holdings in Edwards Lifesciences were worth $2,386,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Arizona State Retirement System lifted its stake in Edwards Lifesciences by 0.8% in the 1st quarter. Arizona State Retirement System now owns 173,090 shares of the medical research company's stock worth $12,546,000 after purchasing an additional 1,363 shares in the last quarter. Diversify Wealth Management LLC lifted its stake in Edwards Lifesciences by 22.8% in the 1st quarter. Diversify Wealth Management LLC now owns 45,982 shares of the medical research company's stock worth $3,508,000 after purchasing an additional 8,541 shares in the last quarter. Cerity Partners LLC lifted its stake in Edwards Lifesciences by 67.9% in the 1st quarter. Cerity Partners LLC now owns 212,923 shares of the medical research company's stock worth $15,433,000 after purchasing an additional 86,089 shares in the last quarter. Telos Capital Management Inc. lifted its stake in Edwards Lifesciences by 7.1% in the 1st quarter. Telos Capital Management Inc. now owns 55,259 shares of the medical research company's stock worth $4,005,000 after purchasing an additional 3,665 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $369,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on EW shares. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research report on Friday, April 25th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Finally, Evercore ISI boosted their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $81.00.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the transaction, the chief financial officer directly owned 41,098 shares of the company's stock, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,848 shares of company stock worth $2,314,488. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE:EW traded up $0.26 during mid-day trading on Friday, hitting $76.44. The stock had a trading volume of 4,816,601 shares, compared to its average volume of 5,284,402. The stock has a market capitalization of $44.84 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.84 and a beta of 1.11. The company has a 50 day simple moving average of $76.50 and a 200-day simple moving average of $73.44. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $88.50. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the firm earned $0.66 EPS. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.